Infectologia
Opinião | COVID ESTEROIDE-2: dobro de esteroide, dobro de diversão? – “Dexametasona na dose de 6 mg/dia isoladamente parece ser subótima para a maioria dos pacientes com pneumonia por COVID. Já na dose de 12 mg/dia parece fornecer uma imunomodulação de intensidade razoável.”
25 Out, 2021 | 13:08hCOVID STEROID-2: Double the steroid, double the fun? – PulmCrit
Comentário no Twitter
COVID-STEROID 2
🥈5% lower mortality with 12 mg dexamethasone (vs 6 mg) – which is *huge* – but p=0.09 😩
🥈RCTs with toci/bari show that 6 mg dex alone is suboptimal.
🥈If using dex monotherapy, 12 mg is now a sensible dose for sicker pts.
Fresh blog: https://t.co/oPz7vAYHGN pic.twitter.com/diDqqUxSTC— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) October 23, 2021
Revisão | Envolvimento cardíaco nas implicações de longo prazo da COVID-19.
25 Out, 2021 | 13:06hCardiac involvement in the long-term implications of COVID-19 – Nature Reviews Cardiology
Vacina da AstraZeneca não se associou a taxas reduzidas de fertilidade nem a desfechos adversos ao nascimento.
25 Out, 2021 | 13:05hFertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination – The Lancet
Conteúdos relacionados:
Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.
Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.
5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.
CDC Guidance: Pregnant people should be vaccinated against COVID-19.
Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.
Comentário no Twitter
New research letter: Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. Authors analysed pregnancies occurring in four ongoing clinical trials in the UK, Brazil, and South Africa. https://t.co/hDM1olKts9@OxfordVacGroup | #COVID19 #AstraZeneca pic.twitter.com/m5qvWhPcph
— The Lancet (@TheLancet) October 23, 2021
Como identificar quando a Covid-19 deixará de ser “pandêmica” para se tornar “endêmica”.
25 Out, 2021 | 13:03hHow you’ll know when Covid-19 has gone from “pandemic” to “endemic” – Vox
Metade das doses, um terço das doses, doses de criança: a entrega da vacina contra Covid chega a outro nível de dificuldade.
25 Out, 2021 | 13:02hHalf doses, third doses, kids’ doses: Covid vaccine delivery goes next-level difficult – STAT
Coronavírus: moradores da China começam a receber as doses de reforço da vacina.
25 Out, 2021 | 13:01hCoronavirus: Chinese residents start receiving vaccine boosters – South China Morning Post
Orientação provisória de 2021 para prestadores de serviços de saúde sobre suporte cardíaco básico e avançado em adultos, crianças e recém-nascidos com COVID-19 suspeita ou confirmada.
25 Out, 2021 | 13:00hComentário: CPR on a COVID Patient: Not a Moment to Waste Looking for PPE: Updated AHA guidance says resuscitation should not be delayed by mask availability – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter (fio – clique para saber mais)
(1/2) NEW! The AHA has published its 2021 interim CPR guidance for #HCPs who treat cardiac arrest patients with suspected or confirmed #COVID19. The paper in @CircOutcomes is an update to the 2020 Interim CPR Guidance: https://t.co/tuTwWkE0dL. pic.twitter.com/B1el7dCKJM
— AHA CPR & First Aid (@HeartCPR) October 13, 2021
M-A | Em pacientes com bacteriemia por Staphylococcus aureus, a terapia combinada não reduz a mortalidade e está associada a riscos aumentados de eventos adversos.
25 Out, 2021 | 12:50hA custo-efetividade da cefazolina comparada com penicilinas antiestafilocócicas no tratamento da bacteriemia por Staphylococcus aureus sensível à meticilina.
25 Out, 2021 | 12:48hConteúdos relacionados:
Meta-Analysis: Cefazolin vs. Antistaphylococcal Penicillins for MSSA Bacteremia
Comentários no Twitter
While Cefazolin and anti-staphylococcal penicillins (ASPs), such as nafcillin, are the preferred treatments for MSSA bacteremia it looks more and more like Cefazolin is really the preferred approach. https://t.co/6FVVEWMxBY
— Daniel Griffin MD PhD (@DanielGriffinMD) October 8, 2021
New in OFID: The use of cefazolin is a cost-effective strategy for the treatment of methicillin-sensitive S. aureus bacteremia and, when clinically appropriate, results in health care cost-savings.
📄: https://t.co/lRfsZdMjLJ#IDSAJournals @PaulSaxMD @DrJLi @ElMylonakis pic.twitter.com/hhzik4ppUW
— IDSA (@IDSAInfo) October 8, 2021
[Comunicado de imprensa – ainda não publicado] Um estudo de fase 3, com mais de 10.000 participantes, mostrou que a dose de reforço com a vacina da Pfizer/BioNTech teve eficácia de 95,6% contra Covid-19; houve 5 casos de doença no grupo com dose de reforço e 109 casos no grupo-controle, sem classificação quanto à gravidade da doença.
22 Out, 2021 | 12:31h
Comentários no Twitter
This will presumably mean everyone gets boosters early next year. That’s great, because they do work. Except it’s likely to be boosters for rich countries at the expense of primary vaccination for poorer countries. You won’t stop the pandemic when half the world is unvaccinated https://t.co/F31DMSI2zf
— Niall Conroy (@NICU_doc_salone) October 21, 2021
The 1st randomized trial of a booster (3rd) shot in 10,000 people, placebo-controlled, shows 95.6% efficacy, with 5 cases (Pfizer vaccine) vs 109 in placebo group, Delta variant, broad benefit across age groups https://t.co/TQpF35d8Jk pic.twitter.com/3RkqvXNfsU
— Eric Topol (@EricTopol) October 21, 2021